Journal of controlled release : official journal of the Controlled Release Society
Cure8 research brief
Why This Matters
Oral delivery of protective proteins or biologic therapies could make future IBD treatments easier to take and better at reaching the gut lining.
This study shows a new molecular carrier that protected an enzyme in stomach-like conditions and improved inflammation in a mouse colitis model, suggesting the approach may be worth further study.
Who Should Pay Attention
Researchers working on drug delivery or IBD therapeutics, translational scientists, and clinicians interested in emerging oral biologic formulations. Patients and caregivers following early-stage IBD treatment research may find it of interest.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This preclinical journal article (abstract provided) reports a chemistry and delivery-platform study: researchers synthesized cyclic oligomeric squaramides (COS) that form supramolecular assemblies and noncovalently complex with a model protein (superoxide dismutase, SOD).
In cell studies the COS/SOD complexes increased intracellular SOD signal, reduced reactive oxygen species and inflammatory responses, and in a mouse model of colitis (DSS-induced) oral COS/SOD improved disease activity, colon appearance, inflammatory markers, and barrier-related outcomes.
The work is presented as a platform for oral protein formulation and delivery rather than as a clinical treatment. The abstract describes formulation chemistry, in vitro cell assays, stability in simulated gastric fluid, and efficacy signals in an animal colitis model. It does not report human data or clinical trial results.
If you follow IBD research, this is early-stage, preclinical work exploring a new oral-delivery method that might eventually allow protective proteins or biologics to be given by mouth.
Keep In Mind
This is preclinical, based on chemistry, cell assays, and a mouse model (DSS colitis). Results in animals often do not predict human outcomes; safety, dosing, and effectiveness in people would require extensive further testing. The abstract, not a full clinical report, was the source for this summary.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of controlled release : official journal of the Controlled Release Society
AuthorsZhongqi Yao, Ningning Yue, Mingfei Chen +3 more
InstitutionSchool of Emergent Soft Matter, South China University of Technology, Guangzhou 510640, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 6, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of competing interest The authors declare no conflict of interest.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Probiotic extracellular vesicles loaded with multifunctional nanozymes for inflammatory bowel disease treatment
The study explores a novel, combined nanozyme + microbiome-derived vesicle approach aimed at reducing oxidative stress and modulating inflammation in IBD — mechanisms that are relevant to disease pathways and future...
Glucose-derived ultra-small carbon nanozymes for treating inflammatory bowel disease.
Researchers are exploring new antioxidant nanozymes that can be given orally to reduce intestinal inflammation in lab models. If these approaches eventually translate to humans, they could become an additional strategy...
Identification of CD40 as the target of artemisinin via targeted degradomics for ulcerative colitis.
This study suggests an existing antimalarial drug, artemisinin, may reduce inflammation and improve gut barrier function in a mouse model of ulcerative colitis by targeting CD40 — a pathway relevant to immune-driven gut...